Filing Flows › 4D Molecular Therapeutics (FDMT) › Q1 2026 › vs Q1 2025
4D Molecular Therapeutics (FDMT) Q1 2026 vs Q1 2025 (year over year)
4D Molecular Therapeutics's revenue rose $3.0M (218×) from $14K in Q1 2025 to $3.0M in Q1 2026.
4D Molecular Therapeutics, Q1 2026: revenue $3.0M (218× year over year), net loss $68.8M, operating cash flow −$68.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.0M | $14K | $3.0M | 218× |
| Other income, net | $4.9M | $5.6M | −$789K | -14% |
| Net loss | $68.8M | $48.0M | $20.8M | +43% |
| Costs & expenses | $76.7M | $53.6M | $23.0M | +43% |
| Operating costs | $76.7M | $53.6M | $23.0M | +43% |
| Research & development | $65.0M | $40.7M | $24.3M | +60% |
| General & admin | $11.7M | $12.9M | −$1.2M | -10% |
| Operating cash sources | $73.8M | $55.8M | $18.1M | +32% |
| Depreciation & amortization | $1.3M | $1.1M | $218K | +21% |
| Share-based compensation | $4.5M | $7.0M | −$2.5M | -36% |
| Cash used in operations | $68.1M | $47.8M | $20.4M | +43% |
| Net loss absorbed | $68.8M | $48.0M | $20.8M | +43% |
| Working capital & other | $5.1M | $7.8M | −$2.7M | -35% |
Questions
How much did 4D Molecular Therapeutics's revenue grow year over year in Q1 2026?
4D Molecular Therapeutics's revenue rose $3.0M (218×) from $14K in Q1 2025 to $3.0M in Q1 2026.